BRPI0914209A2 - epidermal growth factor receptor inhibitor, cell line, pharmaceutical composition, inhibitor and an antibody uses and method - Google Patents

epidermal growth factor receptor inhibitor, cell line, pharmaceutical composition, inhibitor and an antibody uses and method

Info

Publication number
BRPI0914209A2
BRPI0914209A2 BRPI0914209A BRPI0914209A BRPI0914209A2 BR PI0914209 A2 BRPI0914209 A2 BR PI0914209A2 BR PI0914209 A BRPI0914209 A BR PI0914209A BR PI0914209 A BRPI0914209 A BR PI0914209A BR PI0914209 A2 BRPI0914209 A2 BR PI0914209A2
Authority
BR
Brazil
Prior art keywords
inhibitor
pharmaceutical composition
cell line
growth factor
factor receptor
Prior art date
Application number
BRPI0914209A
Other languages
Portuguese (pt)
Inventor
Ariel Tavalera Pérez
Arlhee Díaz Miqueli
Ernesto Moreno Frías
Greta Garrido Hidalgo
José Enrique Montero Casimiro
Rolando Perez Rodríguez
Yildian Díaz Rodríguez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BRPI0914209A2 publication Critical patent/BRPI0914209A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
BRPI0914209A 2008-06-20 2009-06-22 epidermal growth factor receptor inhibitor, cell line, pharmaceutical composition, inhibitor and an antibody uses and method BRPI0914209A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20080117 2008-06-20
PCT/CU2009/000004 WO2009152783A1 (en) 2008-06-20 2009-06-22 Inhibitors of the epidermal growth factor receptor (egfr) with cytostatic action and their uses in tumour therapy

Publications (1)

Publication Number Publication Date
BRPI0914209A2 true BRPI0914209A2 (en) 2015-11-03

Family

ID=41433718

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914209A BRPI0914209A2 (en) 2008-06-20 2009-06-22 epidermal growth factor receptor inhibitor, cell line, pharmaceutical composition, inhibitor and an antibody uses and method

Country Status (5)

Country Link
BR (1) BRPI0914209A2 (en)
CO (1) CO6331302A2 (en)
MX (1) MX2010014543A (en)
TW (1) TWI500630B (en)
WO (1) WO2009152783A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
CU23612A1 (en) * 2006-09-29 2010-12-08 Centro Inmunologia Molecular THERAPEUTIC COMBINATIONS TO ENHANCE THE EFFECT OF THERAPY WITH ANTIBODIES AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR

Also Published As

Publication number Publication date
WO2009152783A1 (en) 2009-12-23
MX2010014543A (en) 2011-04-05
TWI500630B (en) 2015-09-21
CO6331302A2 (en) 2011-10-20
TW201011046A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
BRPI0908637A2 (en) compound; pharmaceutical composition thereof and method for inhibiting cell proliferation in an individual.
BRPI0913739A2 (en) Liquid composition, method, and use of composition
BRPI0924177A2 (en) Polypeptides, their method of preparation, their composition, nucleotide sequence and use
BRPI0819936A2 (en) Pharmaceutical preparation, method for producing dendritic cells, dendritic cells, pharmaceutical composition, and use of a dendritic cell or preparation.
BRPI1007005A2 (en) isolated antibody, isolated nucleic acid n vector, isolated cell, isolated cell line, pharmaceutical composition, and use of an anti-il-6 antibody
BRPI0922106A2 (en) isolated monoclonal antibody, isolated nucleic acid molecule, host cell, method for producing an isolated monoclonal antibody, pharmaceutical composition, and use of the composition
BRPI0918768A2 (en) recombinant epidermal growth factor receptor antibody compositions.
BRPI0916964A2 (en) polypeptide, antibody, nucleic acid, vector, host cell, method for making a polypeptide, composition and use of the polypeptide
BRPI0918359A2 (en) compound, agrochemical composition, use of agrochemical composition and method for preparation of compound
DK3067064T3 (en) MODIFIED RSV-F PROTEINS AND PROCEDURES FOR USE THEREOF
BRPI0924183A2 (en) protein kinase inhibitors, crystalline forms, pharmaceutical formulations and use
BRPI1010798A2 (en) closure, retainer, and method of use
BRPI0919575A2 (en) Method and composition
BRPI1005322A2 (en) antibody, pharmaceutical composition and use of at least one antibody
DK2186269T3 (en) System-level information for discontinuous reception, cell re-selection and RACH
EP2374871A4 (en) Pluripotent stem cells, method for preparation thereof and uses thereof
DK2252633T3 (en) Anti-TrkA antibodies and derivatives thereof
DK3196309T3 (en) THRAUSTOCHYTRIDES, FATIC ACID COMPOSITIONS, AND METHODS FOR PREPARING AND USING THEREOF
BRPI0809573A2 (en) composition and method
BRPI0823277A2 (en) Composition and method
AP2011005665A0 (en) Detection of HIV-related proteins in urine.
BRPI0916787A2 (en) article and method for making an article
BRPI0816151A2 (en) one-well usable valve, one-well usable system, and one-well usable method
BR112013008255A2 (en) isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
BRPI0919832A8 (en) fibroblast growth factor receptor (fgfr-3) inhibitors and treatment methods.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.